Quell TX Logo (RGB)-100.jpg
Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR-Treg Cell Therapy, into Efficacy Cohort of LIBERATE Phase 1/2 Trial in Liver Transplant Patients
June 04, 2024 13:30 ET | Quell TX
Progress in the LIBERATE trial was presented at the American Transplant Congress today London, UK– June 4, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered...
CytoSorbents New Logo - 2021.png
CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease
July 11, 2023 07:00 ET | CytoSorbents
PRINCETON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CloudMedx Working With UCSF to Deploy AI Tools to Support the Management of Liver Cancer Patients Awaiting Liver Transplant
August 02, 2018 17:21 ET | CloudMedx Inc.
PALO ALTO, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- CloudMedx, a healthcare AI company that provides real time and actionable insights to the healthcare industry, today announced it is working with...